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Abstract
Autonomic dysfunction is a common non-motor symptom in Parkinson’s disease (PD). Dopamine and serotonin are known 
to play a role in autonomic regulation, and, therefore, PD-related degeneration of serotonergic and dopaminergic neurons 
in these regions may be associated with autonomic dysfunction. We sought to clarify the association between extrastriatal 
serotonergic and striatal dopaminergic degeneration and the severity of autonomic symptoms, including gastrointestinal, 
pupillomotor, thermoregulatory, cardiovascular, and urinary dysfunction. We performed hierarchical multiple regression 
analyses to determine the relationships between (extra)striatal serotonergic and dopaminergic degeneration and autonomic 
dysfunction in 310 patients with PD. We used  [123I]FP-CIT SPECT binding to presynaptic serotonin (SERT) and dopa-
mine (DAT) transporters as a measure of the integrity of these neurotransmitter systems, and the SCOPA-AUT (Scales for 
Outcomes in Parkinson’s Disease—Autonomic) questionnaire to evaluate the perceived severity of autonomic dysfunction. 
Motor symptom severity, medication status, and sex were added to the model as covariates. Additional analyses were also 
performed using five subdomains of the SCOPA-AUT: cardiovascular, gastrointestinal, urinary, thermoregulatory, and 
pupillomotor symptoms. We found that autonomic symptoms were most significantly related to lower  [123I]FP-CIT binding 
ratios in the right caudate nucleus and were mainly driven by gastrointestinal and cardiovascular dysfunction. These results 
provide a first look into the modest role of dopaminergic projections towards the caudate nucleus in the pathophysiology of 
autonomic dysfunction in PD, but the underlying mechanism warrants further investigation.
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Introduction
Besides the characteristic motor symptoms, Parkinson’s 
disease (PD) patients also frequently suffer from a vari-
ety of non-motor complaints including cognitive decline, 
neuropsychiatric problems, and autonomic dysfunction [1]. 
Autonomic dysfunction is often one of the earliest manifes-
tations of PD. Symptoms of autonomic failure can be car-
diovascular, gastrointestinal, urogenital, thermoregulatory, 
pupillary, respiratory, sexual, or sleep related [2]. The symp-
toms typically worsen with progression of the disease, and 
the use of dopamine replacement therapy may also contrib-
ute [3]. Examples of symptoms include dysmotility of the 
gastrointestinal tract, abnormal sweating patterns, detrusor 
overactivity, and orthostatic hypotension [4–6].
Serotonin (5-hydroxytryptamine; 5-HT) has an impor-
tant role in the regulation of the autonomic nervous system 
(ANS). Serotonergic neurons originating from the nucleus 
raphe obscurus and raphe pallidus have projections to 
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autonomic nuclei in the medulla and spinal cord. These 
serotonergic neurons also receive input from brain areas 
important for autonomic regulation in the brainstem, fore-
brain, and hypothalamus [7, 8]. Serotonin is also involved 
in numerous descending myenteric interneurons that 
innervate the enteric nervous system [9]. Increasing or 
decreasing serotonin signalling affects heat or cold toler-
ance [10, 11], peristalsis [9], urine storage [12, 13], and 
blood pressure [14]. In rodents, stimulating serotonergic 
neurons in the hypothalamus alters energy metabolism and 
cardiovascular functioning [15, 16]. Dopamine has also 
been found to play a role in the ANS [17]. Cholinergic 
myenteric neurons mediate the vagal excitatory effects, 
especially in the stomach and oesophagus [18]. Some 
myenteric neurons are dopaminergic, and dopamine affects 
gastrointestinal motility via presynaptic D2 receptors by 
inhibiting acetylcholine release [17]. Striatal D2 receptors 
are also involved in the salivary response [19], the mictu-
rition reflex and detrusor activity [20], and central blood 
pressure and heart rate regulation [21].
Nuclear imaging is routinely used to visualize and meas-
ure the integrity of these neurotransmitter systems, using 
radiotracers that bind to the serotonin (SERT) and dopamine 
(DAT) transporters in the presynaptic terminal of serotoner-
gic and dopaminergic neurons, respectively. Single-photon 
emission computed tomography (SPECT) scans using a 
radiotracer with high affinity for the DAT can be used to 
detect a loss of nigrostriatal cells in early PD cases, even in 
the premotor phase [22]. A commonly used DAT tracer is 
 [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)
nortropane, or  [123I]FP-CIT (or  [123I]ioflupane). This tracer 
is predominantly useful for assessing dopamine integrity in 
the striatum, but also has a modest affinity for the SERT 
located on the presynaptic membrane of serotonergic neu-
rons such as within the (hypo)thalamus and midbrain [23].
Nuclear imaging has previously been used to show sero-
tonergic as well as dopaminergic loss in PD [24, 25]. Nev-
ertheless, to our knowledge, no study has yet investigated 
the association between the integrity of the serotonergic 
system and autonomic dysfunction in PD using nuclear 
imaging. Recent studies have shown relationships between 
constipation [26] and urinary symptoms [27] and reduced 
striatal DAT availability, but more research is needed to 
confirm these findings. In the current study,  [123I]FP-CIT 
SPECT imaging was used to investigate the relationship 
between extrastriatal SERT availability, as well as striatal 
DAT availability, and the severity of autonomic symptoms 
in PD. The aim was to provide insight into the pathophysi-
ology of autonomic dysfunction in PD, and evaluate the 
involvement of these two neurotransmitter systems. Based 
on previous studies, we hypothesized that lower SERT 
binding in the hypothalamus and other extrastriatal areas 
would be associated with increased autonomic symptoms. 
Likewise, we hypothesized that lower striatal DAT binding 
would be associated with increased autonomic symptoms.
Methods
Participants
There were three inclusion criteria for this study: patients 
must (1) have been diagnosed with idiopathic PD; (2) have 
an available  [123I]FP-CIT SPECT; (3) have provided writ-
ten informed consent in accordance with the declaration of 
Helsinki to use their medical information obtained during 
routine clinical care in the outpatient clinic for research 
purposes. Imaging data and clinical data were obtained 
through the outpatient clinic for movement disorders of 
the department of Neurology, Amsterdam UMC, location 
VUmc, The Netherlands in the period from 2008 to 2018.
Patients were excluded if they were taking any medi-
cation during the  [123I]FP-CIT SPECT scan that could 
influence the ability of the  [123I]FP-CIT tracer to bind to 
DAT or SERT, such as SSRIs or serotonin–norepinephrine 
reuptake inhibitors (SNRIs) [28]. Patients without a valid 
SCOPA-AUT (Scales for Outcomes in Parkinson’s Dis-
ease—Autonomic) questionnaire to measure the severity 
of autonomic dysfunction were also excluded. Figure 1 
shows the flowchart of inclusion and exclusion of patients.
Fig. 1  Inclusion and exclusion of patients. SCOPA-AUT Scales for 
Outcomes in Parkinson’s Disease—Autonomic, SPECT single-photon 
emission computed tomography
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Measurements
Autonomic symptoms were evaluated using the SCOPA-
AUT, a questionnaire designed and validated by Visser 
et al. [29] that evaluates the severity of gastrointestinal, 
urinary, cardiovascular, thermoregulatory, pupillomotor, 
and sexual symptoms. Only items 1–21 were used for 
these analyses, because items 22–25 regarding sexual 
dysfunction had low response rates. Up to three miss-
ing items were accepted, in which case the values were 
imputed with the mean score of the available items. We 
used the Unified Parkinson’s Disease Rating Scale—
motor section (UPDRS-III) to assess the severity of motor 
symptoms of patients, thereby providing an indication of 
the disease severity [30]. The UPDRS-III was adminis-
tered while patients were on dopaminergic medication. 
Imputation of missing data was not performed on the 
UPDRS-III, as this was considered to be unreliable for 
this scale. We also measured disease severity using the 
Hoehn and Yahr scale [31] and subjective disease dura-
tion. To quantify the medication usage of patients, the 
l-dopa equivalent daily dose (LEDD) was calculated [32]. 
To assess the global cognitive functioning of patients, we 
used the Mini-Mental State Examination (MMSE) [33]. 
These measurements were performed on the same day as 
the SPECT scan.
Image acquisition and preprocessing
All patients orally received potassium perchlorate to 
prevent iodide uptake in the thyroid. A bolus of  [123I]
FP-CIT tracer was injected intravenously 3 h before the 
scan, with a dosage of approximately 185 MBq (specific 
activity > 185 MBq/nmol; radiochemical purity > 99%; 
produced as DaTSCAN according to GMP criteria at GE 
Healthcare, Eindhoven, The Netherlands). Static images 
were acquired using a single dual-head gamma camera 
with a fan-beam collimator, with a reconstructed voxel 
size of 3.9 mm3, and a pixel matrix of 128 × 128. After 
attenuation correction, filtered back projection with a 
Butterworth filter (order 8, cut-off 0.6 cycles/cm) was 
used for reconstruction of the scans. The scans were 
manually reoriented to align the left and right striatum 
according to the anterior–posterior commissure (AC-PC) 
line. Non-specific binding in the cerebellum was used as 
a reference (REF; WFU Pickatlas, AAL atlas; bilateral 
Crus II). Binding ratios were calculated, defined as the 
ratio between tracer bound specific to SERT or DAT and 
non-specific binding [(ROI − REF)/REF], to determine 
the availability of the SERT and DAT in extrastriatal and 
striatal regions, respectively.
Regions of interest
The striatal left and right caudate nucleus and posterior 
putamen, the extrastriatal hypothalamus (left and right com-
bined), midbrain, and left and right thalamus were defined 
as the regions of interest (ROIs). The caudate nucleus, mid-
brain, and thalamus were defined from the automated ana-
tomical labelling (AAL) atlas. The posterior putamen ROI 
was based on the putamen ROI from the AAL atlas, in a way 
that it comprised only voxels posterior to the anterior com-
missure, as previously described [34]. This was done due to 
the existence of functional differences between the anterior 
and posterior region, and because the extent of dopamine 
depletion is more severe in the posterior putamen, correlat-
ing with the severity of motor symptoms [35]. The anterior 
putamen was not included in the analyses. The hypothalamus 
ROI was based on the Talairach Daemon (TD) Brodmann 
area + atlas, and was dilated twice due to its small size, as 
previously described [23]. All ROIs were implemented in 
the WFU Pickatlas (version 3.0.5; Wake Forest University).
Data analysis
We used the Statistical Package for the Social Sciences 
(SPSS) version 22 (IBM Inc., Armonk, NY, USA) for the 
analyses. Assumptions for regression analyses were checked 
and met. Hierarchical multiple regression analyses with the 
‘enter’ method were performed, with the SCOPA-AUT 
scores as the independent variable and  [123I]FP-CIT binding 
ratios in each ROI as the outcome variables. Age was added 
as a covariate to the first step of the model to account for 
the decline in SERT and DAT availability with aging [36].
For the regression analyses, adjusted p values were cal-
culated to correct for multiple comparisons with simple 
interactive statistician analysis (SISA, https ://www.quant 
itati veski lls.com/sisa/calcu latio ns/bonhl p.htm). This tool 
uses the mean association between variables that are mutu-
ally correlated (binding ratios in our ROIs) for the alpha 
correction (r = 0.73 for the extrastriatal ROIs, and r = 0.84 
for the striatal ROIs), and allows for a less stringent cor-
rection than the Bonferroni method for multiple compari-
sons that assumes independence. For the four extrastriatal 
ROIs, this resulted in an adjusted statistical threshold of 
padj < 0.035 and for striatal ROIs this resulted in a threshold 
of padj < 0.040. A p value between padj and p = 0.050 was 
considered a trend.
Sensitivity analyses were done by separately adding 
measures of disease severity (UPDRS-III scores, H&Y stage 
or subjective disease duration), medication status or gender 
as covariates of no interest to the third step of the model. The 
analyses were also repeated in a subsample of unmedicated 
patients, and in patients with MMSE score > 24, because 
patients scoring equal to, or below 24 may suffer from 
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cognitive impairments that impede their ability to correctly 
interpret or answer the questions of the SCOPA-AUT.
Post-hoc analyses were done with the cardiovascular, gas-
trointestinal, urinary, thermoregulatory, and pupillomotor 
subdomains of the SCOPA-AUT.
Statistical Parametric Mapping (SPM) version 12 imaging 
software was used to confirm the significant findings of the 
ROI analyses, using voxel-based analyses with age as a nui-
sance covariate. An explicit mask was placed for each ROI, 
in which we performed the voxel-based analysis. The masks 
were the same as in the ROI-based analysis. The statistical 
threshold was set to p < 0.05, family-wise error (FWE), cor-
rected for multiple comparisons.
Results
Clinical characteristics
In total, 384 patients were assessed for eligibility. Due to a 
non-valid SCOPA-AUT, the use of SSRIs or SNRIs, or tech-
nical difficulties during scanning, 74 patients were excluded 
(see Fig. 1). The clinical characteristics of the remaining 
310 patients that were included are summarized in Table 1.
At least one autonomic symptom was experienced by 307 
(99%) patients, of whom 260 (83.9%) had gastrointestinal 
symptoms, 304 (98.1%) had urinary symptoms, 171 (55.2%) 
had cardiovascular symptoms, 236 (76.12%) had thermoreg-
ulatory symptoms, and 122 (39.4%) had pupillomotor symp-
toms. The majority of patients (66.8%) were not yet using 
dopaminergic medication. SCOPA-AUT scores correlated 
positively with UPDRS-III scores (r = 0.316, p < 0.001), 
disease duration (r = 0.216, p < 0.001) age (r = 0.253, 
p < 0.001), and LEDD (r = 0.212, p < 0.001), likely reflecting 
increased autonomic dysfunctions with disease progression.
ROI and voxel‑based analyses
In the total sample of PD patients, the SCOPA-AUT scores 
showed a significant negative association with  [123I]FP-
CIT binding ratios in the bilateral posterior putamen (left: 
β = − 0.143, p = 0.015, R2 = 0.029, ΔR2 = 0.019; right: 
β = − 0.147, p = 0.012, R2 = 0.035, ΔR2 = 0.020) and bilat-
eral caudate nucleus (left: β = − 0.150 p = 0.006, R2 = 0.140, 
ΔR2 = 0.021; right: β = − 0.188, p = 0.001, R2 = 0.102, 
ΔR2 = 0.033). These associations all reflect a reduced stri-
atal DAT availability with increasing autonomic dysfunc-
tion. A trend-significant negative association was found with 
SERT availability in the left thalamus and the hypothalamus 
(see Table 2). In line with these results, the SCOPA-AUT 
scores showed a significant negative association with voxel-
based  [123I]FP-CIT binding in the right caudate nucleus, par-
ticularly in the posterior caudate head (see supplementary 
Table 2 and Fig. 2). This relationship stayed intact when 
UPDRS-III was added to adjust for disease severity 
(pFWE = 0.047, T = 3.45, x/y/z = 16/4/20). No significant asso-
ciation was observed for hypothalamic binding. 
Sensitivity analyses
When separately adding the UPDRS-III score (N = 287, 
see Fig. 2) and medication status (N = 298) to the model, 
only the associations between autonomic dysfunction and 
 [123I]FP-CIT binding ratios in the right caudate nucleus 
remained (UPDRS-III: β = − 0.127, p = 0.030, R2 = 0.174, 
Table 1  Sample characteristics
For all variables except number of patients, the mean (standard devia-
tion) is reported
SCOPA-AUT Scales for Outcomes in Parkinson’s Disease—Auto-
nomic; UPDRS-III Unified Parkinson’s Disease Rating Scale, Sect. 3 
(motor evaluation); MMSE Mini-Mental State Examination; LEDD 
levodopa equivalent daily dose; BR  [123I]FP-CIT binding ratio
a 24 patients had missing data
b 24 patients had missing data
c 63 patients had missing data
d 40 patients had missing data
e 12 patients had missing data
f 10 patients had missing data
g 1 patient had missing data
N patients (% male) 310 (62.6%)
Age (years) 66.35 (± 10.80)
SCOPA-AUT score 13.15 (± 7.84)
UPDRS-III  scorea 24.37 (± 12.52)









Disease duration (years)c 3.68 (± 4.26)
MMSE  scored 27.60 (± 3.24)
LEDD (mg/day)e 136.70 (± 258.09)
BDI  scoref 10.47 (± 7.59)
BR left thalamus 0.75 (± 0.18)
BR right thalamus 0.74 (± 0.19)
BR  hypothalamusg 0.66 (± 0.21)
BR midbrain 0.76 (± 0.16)
BR left caudate nucleus 1.81 (± 0.43)
BR right caudate nucleus 1.86 (± 0.44)
BR left posterior putamen 1.59 (± 0.41)
BR right posterior putamen 1.48 (± 0.41)
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ΔR2 = 0.067; medication status: β = − 0.131, p = 0.025, 
R2 = 0.131, ΔR2 = 0.029). Using Hoehn and Yahr stage or 
disease duration to correct for disease severity instead of 
the UPDRS-III score did not change these results (Hoehn 
and Yahr: β = − 0.156, p = 0.010, R2 = 0.160, ΔR2 = 0.035; 
disease duration: β = − 0.147, p = 0.021, R2 = 0.161, 
ΔR2 = 0.048). Adding gender as a covariate also did not 
significantly alter the results.
Additional analyses were done with subsamples 
of patients. When patients with signs of dementia 
(MMSE  ≤  24; N = 64) were excluded, SCOPA-AUT 
scores showed a statistically significant negative asso-
ciation with  [123I]FP-CIT binding ratios in the left thala-
mus (β = − 0.169, p = 0.011, R2 = 0.040, ΔR2 = 0.026), left 
posterior putamen (β = − 0.152, p = 0.022, R2 = 0.024, 
ΔR2 = 0.021), and right caudate nucleus (β = − 0.171, 
p = 0.008, R2 = 0.088, ΔR2 = 0.027). SCOPA-AUT scores 
no longer showed a significant association with  [123I]FP-
CIT binding ratios when only medication-free PD patients 
were considered (N = 207).
Subdomains of autonomic dysfunction
To determine which autonomic symptoms drove the associa-
tions, post hoc analyses were performed with subdomains 
of the SCOPA-AUT. These results showed that the reported 
associations with the total SCOPA-AUT (excluding sexual 
dysfunctions) were mainly driven by cardiovascular and gas-
trointestinal symptoms (see supplementary Table 1). Also 
here, adding UPDRS-III scores to adjust for the influence 
of disease severity, only  [123I]FP-CIT binding in the right 
caudate nucleus was significantly associated with auto-
nomic symptoms (cardiovascular symptoms: β = − 0.124, 
p = 0.027, R2 = 0.175, ΔR2 = 0.074; gastrointestinal symp-
toms: β = − 0.187, p = 0.001, R2 = 0.190, ΔR2 = 0.053; see 
supplementary Fig. 1).
Post hoc analyses
One of our previous studies in an overlapping sample 
showed that DAT availability in the right caudate nucleus 
Table 2  Hierarchical multiple 
regression analyses with the 
SCOPA-AUT and each ROI
Hierarchical model, method: enter. N = 310 for all except hypothalamus, where N = 309. SA = SCOPA-AUT 
score, β = standardized regression coefficient, p = significance, R2 = proportion of variance of independent 
variable explained by the regression model. ΔR2 = difference between R2 of model 1 and model 2. The 
most relevant results are highlighted in bold
ROI Step Variable β p R2 ΔR2
Left thalamus 1 Age − 0.133 0.019 0.018
2 Age − 0.102 0.081
SA − 0.122 0.036 0.032 0.014
Right thalamus 1 Age − 0.169 0.003 0.029
2 Age − 0.162 0.006
SA − 0.029 0.624 0.029 0.001
Hypothalamus 1 Age − 0.212 0.000 0.045
2 Age − 0.183 0.002
SA − 0.116 0.045 0.057 0.013
Midbrain 1 Age − 0.041 0.469 0.002
2 Age − 0.025 0.671
SA − 0.064 0.276 0.006 0.004
Left caudate nucleus 1 Age − 0.345 0.000 0.119
2 Age − 0.307 0.000
SA − 0.150 0.006 0.140 0.021
Right caudate nucleus 1 Age − 0.263 0.000 0.069
2 Age − 0.215 0.000
SA − 0.188 0.001 0.102 0.033
Left posterior putamen 1 Age − 0.102 0.072 0.010
2 Age − 0.066 0.256
SA − 0.143 0.015 0.029 0.019
Right posterior putamen 1 Age − 0.122 0.032 0.015
2 Age − 0.084 0.147
SA − 0.147 0.012 0.035 0.020
1927Journal of Neurology (2020) 267:1922–1930 
1 3
was also negatively associated with depressive symptoms 
[37]. Because of potential spatial overlap with the current 
results, additional post hoc analyses were performed to check 
for the influence of depression, using the Beck Depression 
Inventory (BDI). When BDI scores were added to the third 
step of the model,  [123I]FP-CIT binding in the right caudate 
nucleus was no longer associated with SCOPA-AUT scores. 
Nevertheless, our voxel-based analysis (see supplementary 
results) showed that the BDI scores were associated with a 
different—more anteroventral—region within the caudate 
nucleus (x/y/z: 16/16/− 6), than the SCOPA-AUT (x/y/z: 
16/4/20; see supplementary Figs. 2 and 3).
Discussion
The aim of this study was to elucidate the association 
between extrastriatal serotonergic and striatal dopaminergic 
degeneration and the severity of autonomic symptoms. Our 
results confirm our hypothesis that reduced DAT availability 
in the striatum, particularly the caudate nucleus, is associ-
ated with more autonomic symptoms in PD. This associa-
tion was corroborated by our voxel-based analysis and seems 
mainly driven by cardiovascular and gastrointestinal symp-
toms. We also hypothesized that reduced extrastriatal SERT 
availability would be associated with increased autonomic 
failure. However, a weaker relationship was found here, with 
only a trend-significant relationship in the left thalamus and 
hypothalamus. When correcting for disease severity, only 
the relationship in the right caudate nucleus remained intact.
Previous research has suggested the involvement of stri-
atal dopaminergic neurons in a wide range of autonomic 
dysfunctions, including urinary dysfunction [6, 38] and 
hyposalivation [19]. Our association with gastrointesti-
nal symptoms is in accordance with a previous study that 
suggested the involvement of striatal D2 receptors in the 
salivary response through signalling via the globus pallidus 
and mesencephalic reticular formation to the sympathetic 
preganglionic neurons in the spinal cord [19]. A recent DaT 
study also found that gastrointestinal dysfunction, espe-
cially constipation, is associated with striatal dopaminergic 
degeneration [26]. In accordance with our findings, their 
association was stronger in the caudate nucleus than in the 
putamen. Our cardiovascular findings are in accordance 
with a previous study describing the involvement of striatal 
dopamine receptors in central regulation of blood pressure 
and heart rate, possibly through parasympathetic nervous 
activity [21]. Nevertheless, our results conflict with those 
found by Goldstein et al. [39], who reported that the occur-
rence of cardiac denervation is not related to the severity of 
striatal dopaminergic degeneration in PD patients (N = 77). 
Another previous DAT study investigating the association 
between autonomic dysfunction and striatal dopamine deple-
tion found that urinary symptoms, but no other autonomic 
Fig. 2  Partial plot of the association between  [123I]FP-CIT binding ratios in the right caudate nucleus and SCOPA-AUT scores, corrected for age 
and UPDRS-III scores
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symptoms, were associated with reduced dopaminergic 
activity in the putamen [27].
When the association between  [123I]FP-CIT binding 
ratios and autonomic symptoms was adjusted for disease 
severity, only the right caudate nucleus showed a relation-
ship with autonomic dysfunction. It should be noted that, 
as Braak et al. [40] proposed, autonomic symptoms often 
begin before the onset of motor symptoms, and, therefore, 
using motor symptoms to correct for disease severity may 
not be entirely accurate. Most patients in this sample were 
in similar disease stages (H&Y stage 2) when the SPECT 
images were acquired, so adjusting for UPDRS-III scores 
may have resulted in over-correction for disease severity. 
However, when using Hoehn and Yahr stage or subjective 
disease duration to correct for disease severity, the results 
remained the same. When the analyses were repeated with 
only unmedicated patients, no relationships remained sig-
nificant, but this may be due to the reduction in power.
Even though our extrastriatal findings were less robust 
and did not survive the adjustment for disease severity, they 
do support previous research suggesting the involvement 
of serotonergic degeneration in autonomic dysfunction. A 
previous study from our group suggested that loss of SERT-
expressing neurons in the hypothalamus may account for 
dysregulation of the autonomic nervous system in other par-
kinsonian disorders such as multiple system atrophy with 
Parkinsonian features (MSA-P) and progressive supranu-
clear palsy (PSP) [23]. Previous studies also described a 
relationship between blood pressure regulation and serotonin 
levels in the dorsomedial hypothalamus and nucleus tractus 
solitarius, which has projections to the hypothalamus, thala-
mus, and midbrain [14, 41].
This study was one of the first to investigate the associa-
tion between dopaminergic and serotonergic degeneration 
in (extra)striatal areas, especially the hypothalamus, and 
autonomic symptoms in PD using  [123I]FP-CIT SPECT. A 
strength is the large sample size of 310 patients. Another 
strength is the exclusion of patients taking SSRIs or SNIRs, 
as these increase binding of the tracer to DAT by about 10% 
[28]. An additional strength is the corroboration of our find-
ings using voxel-based techniques.
A possible limitation is the use of the SCOPA-AUT, 
which is a self-report questionnaire. Healthy (elderly) con-
trols are also known to score points on the SCOPA-AUT, 
suggesting that not all autonomic dysfunction measured is 
necessarily due to the PD pathology [29]. Nevertheless, it 
has been validated independently and was found to be an 
acceptable, precise, and consistent scale to assess autonomic 
symptoms in PD [42]. A second limitation is the use of a 
single radiotracer to study both striatal dopaminergic and 
extrastriatal serotonergic binding (although this does reduce 
the radiation load).
More research on the mechanisms behind autonomic dys-
function in PD is needed to confirm our findings. Our study 
provides a first look into the associations between dopamin-
ergic and serotonergic degeneration and autonomic dysfunc-
tion, but the observed relationships are modest and require 
replication. Additionally, further research is needed to 
investigate the specific subregion within the caudate nucleus 
that is associated with autonomic symptoms seen in PD, as 
our post hoc voxel-based analyses show that the severity 
of depressive and autonomic symptoms is associated with 
distinct parts of the caudate nucleus. Our results are also in 
need of replication with a tracer that is selective to SERT, 
such as PET scans using  [1 1C ]-3 -am ino -4- (2- dim eth yla min 
ome thy lph eny lsu lfa nyl)-benzonitrile, or  [11C]DASB [43], to 
draw clearer conclusions about the specific involvement of 
serotonergic degeneration in autonomic dysfunction.
In conclusion, autonomic symptoms in PD, particularly 
cardiovascular and gastrointestinal dysfunction, were asso-
ciated with lower striatal  [123I]FP-CIT binding, mainly in 
the right caudate nucleus. These may give a first indication 
that degeneration of the dopaminergic projection towards the 
caudate nucleus is modestly involved in autonomic dysfunc-
tion in PD patients, although the direction of causality and 
the underlying mechanisms need further study.
Funding None.
Compliance with ethical standards 
Conflicts of interest All authors declare that they have no conflict of 
interest.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Reichmann H, Brandt MD, Klingelhoefer L (2016) The nonmotor 
features of Parkinson’s disease: pathophysiology and management 
advances. Curr Opin Neurol 29(4):467–473
 2. Micieli G, Tosi P, Marcheselli S, Cavallini A (2003) Auto-
nomic dysfunction in Parkinson’s disease. Neurol Sci 24(Suppl 
1):S32–S34
1929Journal of Neurology (2020) 267:1922–1930 
1 3
 3. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout 
AM, van Hilten JJ (2007) Patient-reported autonomic symptoms 
in Parkinson disease. Neurology 69(4):333–341
 4. Pellegrini C, Colucci R, Antonioli L, Barocelli E, Ballabeni V, 
Bernardini N, Blandizzi C, de Jonge WJ, Fornai M (2016) Intes-
tinal dysfunction in Parkinson’s disease: lessons learned from 
translational studies and experimental models. Neurogastroenterol 
Motil 28(12):1781–1791
 5. Pfeiffer RF (2012) Autonomic dysfunction in Parkinson’s disease. 
Expert Rev Neurother 12(6):697–706
 6. Sakakibara R, Kishi M, Ogawa E, Tateno F, Uchiyama T, Yama-
moto T, Yamanishi T (2011) Bladder, bowel, and sexual dysfunc-
tion in Parkinson’s disease. Parkinsons Dis 2011:924605
 7. Benarroch EE (2014) Medullary serotonergic system: 
organization, effects, and clinical correlations. Neurology 
83(12):1104–1111
 8. Politis M, Niccolini F (2015) Serotonin in Parkinson’s disease. 
Behav Brain Res 277:136–145
 9. Gershon MD (2004) Review article: serotonin receptors and 
transporters—roles in normal and abnormal gastrointestinal 
motility. Aliment Pharmacol Ther 20(Suppl 7):3–14
 10. Hodges MR, Tattersall GJ, Harris MB, McEvoy SD, Richerson 
DN, Deneris ES, Johnson RL, Chen ZF, Richerson GB (2008) 
Defects in breathing and thermoregulation in mice with near-
complete absence of central serotonin neurons. J Neurosci 
28(10):2495–2505
 11. Lin MT, Tsay HJ, Su WH, Chueh FY (1998) Changes in extra-
cellular serotonin in rat hypothalamus affect thermoregulatory 
function. Am J Physiol 274(5):R1260–R1267
 12. Ito T, Sakakibara R, Nakazawa K, Uchiyama T, Yamamoto T, 
Liu Z, Shimizu E, Hattori T (2006) Effects of electrical stimula-
tion of the raphe area on the micturition reflex in cats. Neurosci-
ence 142(4):1273–1280
 13. Thor KB, Donatucci C (2004) Central nervous system control 
of the lower urinary tract: new pharmacological approaches to 
stress urinary incontinence in women. J Urol 172(1):27–33
 14. Watts SW, Morrison SF, Davis RP, Barman SM (2012) 
Serotonin and blood pressure regulation. Pharmacol Rev 
64(2):359–388
 15. Borgers AJ, Alkemade A, Van de Giessen EM, Drent ML, Booij 
J, Bisschop PH, Fliers E (2013) Imaging of serotonin trans-
porters with [123I]FP-CIT SPECT in the human hypothalamus. 
EJNMMI Res 3(1):34
 16. Horiuchi J, McDowall LM, Dampney RA (2006) Differential 
control of cardiac and sympathetic vasomotor activity from 
the dorsomedial hypothalamus. Clin Exp Pharmacol Physiol 
33(12):1265–1268
 17. Cersosimo MG, Benarroch EE (2008) Neural control of the 
gastrointestinal tract: implications for Parkinson disease. Mov 
Disord 23(8):1065–1075
 18. Cersosimo MG, Benarroch EE (2012) Autonomic involvement 
in Parkinson’s disease: pathology, pathophysiology, clini-
cal features and possible peripheral biomarkers. J Neurol Sci 
313(1–2):57–63
 19. Pazo JH, Belforte JE (2002) Basal ganglia and functions 
of the autonomic nervous system. Cell Mol Neurobiol 
22(5–6):645–654
 20. Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor 
symptoms of Parkinson’s disease: diagnosis and management. 
Lancet Neurol 5(3):235–245
 21. Yeh TL, Yang YK, Chiu NT, Yao WJ, Yeh SJ, Wu JS, Chuang 
JI, Chang SH (2006) Correlation between striatal dopamine D2/
D3 receptor binding and cardiovascular activity in healthy sub-
jects. Am J Hypertens 19(9):964–969
 22. Suwijn SR, de Bruin K, de Bie RM, Booij J (2014) The role of 
SPECT imaging of the dopaminergic system in translational 
research on Parkinson’s disease. Parkinsonism Relat Disord 
20(Suppl 1):S184–S186
 23. Joling M, Vriend C, van den Heuvel OA, Raijmakers P, Jones 
PA, Berendse HW, Booij J (2017) Analysis of extrastriatal (123)
I-FP-CIT binding contributes to the differential diagnosis of 
Parkinsonian diseases. J Nucl Med 58(7):1117–1123
 24. Pagano G, Niccolini F, Fusar-Poli P, Politis M (2017) Serotonin 
transporter in Parkinson’s disease: a meta-analysis of positron 
emission tomography studies. Ann Neurol 81(2):171–180
 25. Joling M, Vriend C, Raijmakers P, van der Zande JJ, Lemstra 
AW, Berendse HW, Booij J, van den Heuvel OA (2019) Striatal 
DAT and extrastriatal SERT binding in early-stage Parkinson’s 
disease and dementia with Lewy bodies, compared with healthy 
controls: an (123)I-FP-CIT SPECT study. Neuroimage Clin 
22:101755
 26. Hinkle JT, Perepezko K, Mills KA, Mari Z, Butala A, Dawson 
TM, Pantelyat A, Rosenthal LS, Pontone GM (2018) Dopamine 
transporter availability reflects gastrointestinal dysautonomia in 
early Parkinson disease. Parkinsonism Relat Disord 55:8–14
 27. Kim R, Jun JS (2019) Association of autonomic symptoms with 
presynaptic striatal dopamine depletion in drug-naive Parkin-
son’s disease: an analysis of the PPMI data. Auton Neurosci 
216:59–62
 28. Booij J, Kemp P (2008) Dopamine transporter imaging with 
[(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl 
Med Mol Imaging 35(2):424–438
 29. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ (2004) 
Assessment of autonomic dysfunction in Parkinson’s disease: 
the SCOPA-AUT. Mov Disord 19(11):1306–1312
 30. Movement Disorder Society Task Force on Rating Scales for 
Parkinson’s Disease (2003) The Unified Parkinson’s Disease 
Rating Scale (UPDRS): status and recommendations. Mov Dis-
ord 18(7):738–750
 31. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Coun-
sell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr 
MD, Seidl L, Movement Disorder Society Task Force on Rat-
ing Scales for Parkinson’s Disease (2004) Movement Disorder 
Society Task Force report on the Hoehn and Yahr staging scale: 
status and recommendations. Mov Disord 19(9):1020–1028
 32. Olde Dubbelink KT, Stoffers D, Deijen JB, Twisk JW, Stam CJ, 
Berendse HW (2013) Cognitive decline in Parkinson’s disease 
is associated with slowing of resting-state brain activity: a lon-
gitudinal study. Neurobiol Aging 34(2):408–418
 33. Mitchell AJ (2013) The Mini-Mental State Examination 
(MMSE): an update on its diagnostic validity for cognitive 
disorders. In: Larner AJ (ed) Cognitive screening instruments. 
Springer, London, pp 15–46
 34. Vriend C, Nordbeck AH, Booij J, van der Werf YD, Pattij T, 
Voorn P, Raijmakers P, Foncke EM, van de Giessen E, Berendse 
HW, van den Heuvel OA (2014) Reduced dopamine transporter 
binding predates impulse control disorders in Parkinson’s dis-
ease. Mov Disord 29(7):904–911
 35. Aarts E, Helmich RC, Janssen MJ, Oyen WJ, Bloem BR, 
Cools R (2012) Aberrant reward processing in Parkinson’s 
disease is associated with dopamine cell loss. Neuroimage 
59(4):3339–3346
 36. van Dyck CH, Malison RT, Seibyl JP, Laruelle M, Klumpp H, 
Zoghbi SS, Baldwin RM, Innis RB (2000) Age-related decline 
in central serotonin transporter availability with [(123)I]beta-
CIT SPECT. Neurobiol Aging 21(4):497–501
 37. Vriend C, Raijmakers P, Veltman DJ, van Dijk KD, van der Werf 
YD, Foncke EM, Smit JH, Berendse HW, van den Heuvel OA 
(2014) Depressive symptoms in Parkinson’s disease are related 
1930 Journal of Neurology (2020) 267:1922–1930
1 3
to reduced [123I]FP-CIT binding in the caudate nucleus. J Neu-
rol Neurosurg Psychiatry 85(2):159–164
 38. Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of 
Parkinson’s disease: dopaminergic pathophysiology and treat-
ment. Lancet Neurol 8(5):464–474
 39. Goldstein DS, Holmes C, Bentho O, Sato T, Moak J, Sharabi Y, 
Imrich R, Conant S, Eldadah BA (2008) Biomarkers to detect 
central dopamine deficiency and distinguish Parkinson dis-
ease from multiple system atrophy. Parkinsonism Relat Disord 
14(8):600–607
 40. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, 
Braak E (2003) Staging of brain pathology related to sporadic 
Parkinson’s disease. Neurobiol Aging 24(2):197–211
 41. Grubb BP, Karas BJ (1998) The potential role of seroto-
nin in the pathogenesis of neurocardiogenic syncope and 
related autonomic disturbances. J Interv Card Electrophysiol 
2(4):325–332
 42. Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, de Pedro-
Cuesta J, Martinez-Martin P, Longitudinal Parkinson’s Disease 
Patient Study, E.L.d.P.c.E.d.P.G. (2010) Independent validation 
of the scales for outcomes in Parkinson’s disease-autonomic 
(SCOPA-AUT). Eur J Neurol 17(2):194–201
 43. Gryglewski G, Rischka L, Philippe C, Hahn A, James GM, Kle-
bermass E, Hienert M, Silberbauer L, Vanicek T, Kautzky A, 
Berroteran-Infante N, Nics L, Traub-Weidinger T, Mitterhauser 
M, Wadsak W, Hacker M, Kasper S, Lanzenberger R (2017) 
Simple and rapid quantification of serotonin transporter binding 
using [(11)C]DASB bolus plus constant infusion. Neuroimage 
149:23–32
